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How mixtures of immune cells associate with cancer cell phenotype and affect pathogenesis
is still unclear. In 15 breast cancer gene expression datasets, we invariably identify three
clusters of patients with gradual levels of immune infiltration. The intermediate immune
infiltration cluster (Cluster B) is associated with a worse prognosis independently of known
clinicopathological features. Furthermore, immune clusters are associated with response to
neoadjuvant chemotherapy. In silico dissection of the immune contexture of the clusters
identified Cluster A as immune cold, Cluster C as immune hot while Cluster B has a pro-
tumorigenic immune infiltration. Through phenotypical analysis, we find epithelial
mesenchymal transition and proliferation associated with the immune clusters and mutually
exclusive in breast cancers. Here, we describe immune clusters which improve the prognostic
accuracy of immune contexture in breast cancer. Our discovery of a novel independent
prognostic factor in breast cancer highlights a correlation between tumor phenotype and
immune contexture.
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The tumor microenvironment influences cancer initiationand progression1,2. In breast cancer, clinicopathologicalcharacteristics such as age, grade, stage, and molecular
subtypes associate with prognosis and drive treatment decisions.
High-throughput gene expression analyses led to a molecular
classification of breast cancers3,4. The five clinically relevant
molecular subtypes: Luminal A, Luminal B, Her2-enriched, Basal-
like, and Normal-like, have different incidences, survival, prog-
nosis, and tumor biology. Such patient stratification has clinical
and economical utility in breast cancer management5.
In addition to cancer cell biology, an inflammatory micro-
environment influences initiation and progression6. The immune
microenvironment surrounding cancer cells can recognize and
inhibit tumor growth7 or promote progression8. It is crucial to
characterize the quality and quantity of immune response at the
tumor site, as it may help to pinpoint patients who could benefit
from immunotherapies and will improve our understanding of
the tumor–host biology.
In breast cancer, high immune infiltration has been associated
with better clinical outcome9,10. In particular, high CD8+ T cell
infltration associate with better overall survival (OS) in estrogen
receptor (ER)-negative patients11,12. In addition, high immune
infiltration has been associated with an increased response to neo-
adjuvant and adjuvant chemotherapy13.
Recently, we and others have demonstrated that transcriptomic
data can be leveraged to dissect the tumor microenvironment14–19.
Such methods have shown that elevated expression of leukocyte
marker genes associates with a lower risk of breast cancer
recurrence14,17,20,21. Notably, Ali et al. and Bense et al. recently
reported through comprehensive studies how specific immune cell
types influence breast cancer outcome14,22. In these studies, the
authors assessed each predicted cell type individually and did not
consider the immune microenvironment as a whole. More studies
are needed to specify the role and the clinical relevance of the
immune contexture in breast cancer.
In the present study, we discover clinically relevant immune
clusters with gradual immune infiltration. In 15 breast cancer
cohorts, spanning 6101 breast cancer samples, the group of
patients with intermediate levels of tumor immune infiltration has
a worse prognosis independently of known prognostic molecular
and clinicopathological features. Through characterization of the
immune composition of the clusters, we find a pro-tumorigenic
immune infiltration associated with the poor prognosis group.
Further phenotypical analyses show two mutually exclusive
aggressive tumor phenotypes in breast cancers, one linked to
epithelial–mesenchymal transition (EMT) and the other to pro-
liferation. Both phenotypes are found in the poor prognosis cluster
on an inactive/pro-tumorigenic immune microenvironment.
Results
Immune clusters in breast cancer. The expression of 760 genes
in 95 formalin-fixed, paraffin-embedded (FFPE) tumor samples
of the MicMa cohort was measured using the nCounter® Pan-
Cancer Immune Profiling array, an array designed to profile
immune infiltration in solid tumors. Seventy-nine of these
95 samples have been previously profiled by Agilent whole-
genome 4 × 44K oligo array23. We first compared the expression
obtained with the two platforms using Pearson and Spearman
correlations and found a high degree of positive correlation
between the genes’ expression values (Supplementary Fig. 1A).
In order to group patients according to their similarity in
expression of the immune-related genes, we performed unsuper-
vised hierarchical clustering of the correlation matrix (Fig. 1a: 95
MicMa-nCounter and Supplementary Fig. 1B; 104 MicMa-
Agilent samples). Silhouette plot analysis from 3 to 10 clusters
indicated that 3 clusters captured best the segmentation of both
the nCounter and the Agilent datasets (Supplementary Fig. 1C,
D). We therefore continued our analyses based on three clusters
of patients. We compared the clustering obtained from FFPE:
MicMa-nCounter, 95 samples (correlation matrix obtained from
the expression of 760 genes on the Immune Profiling array) to the
clustering performed on fresh frozen tissue MicMa-Agilent,
104 samples (correlation matrix obtained from the expression of
the 509 genes on the Immune Profiling array found in all datasets
used in this study). Seventy-nine samples were overlapping in
these two datasets. With different platforms used to measure gene
expression, as well as incomplete overlap in gene lists and samples
used to perform unsupervised clustering, we still found the cluster
assignment for the 79 overlapping samples significantly similar
(Supplementary Table 1 with Fisher exact test <0.0001).
To confirm that the clusters were associated with the tumor
immune microenvironment (Fig. 1b), we used the algorithm
Nanodissect to score for total lymphocyte and myelocyte
infiltration17,24,25. Nanodissect scores were first validated in the
MicMa cohort using the evaluation of immune infiltration of
matched hematoxylin and eosin (H&E) sections analyzed by
experienced pathologists (Fig. 1c and Supplementary Fig. 1E).
We found the three clusters significantly correlated with
Nanodissect lymphocyte (Fig. 1b) and myelocyte (Supplementary
Fig. 1F) scores. In addition, Chi-squared test showed significant
association between clusters and immune infiltration assessed by
experienced pathologists (p < 0.0001). We concluded that Clusters
A–C reflect gradual immune infiltration and were therefore called
immune clusters.
Clusters reflect gradual immune infiltration. We validated the
association between the clusters and lymphoid/myeloid infiltra-
tion using the expression data from nine other cohorts (Supple-
mentary Table 2). As stated above, 509 of the 760 genes on the
nCounter® PanCancer Immune Profiling array were found in all
datasets studied, the expression of these 509 genes was used in the
unsupervised clustering (Fig. 1d and Supplementary Fig. 2A for
the clustering of the METABRIC and The Cancer Genome Atlas
(TCGA) cohorts, respectively). In each cohort, the three clusters
obtained were significantly associated with lymphoid and myeloid
Nanodissect scores (Lymphoid score: METABRIC, Fig. 1e;
TCGA, Supplementary Fig. 2B).
Lymphoid and myeloid infiltrations gradually increased from
Cluster A (blue; low infiltration; cold tumors) to Cluster B (light
blue; intermediate infiltration) and Cluster C (pink; high
infiltration; hot tumors).
For an additional layer of validation, we used the pathological
assessment of immune infiltration in the METABRIC cohort26,
which was significantly associated with the Nanodissect scores
(Fig. 1f and Supplementary Fig. 2C) and with the immune
clusters: Chi-square test between immune clusters and patholo-
gical assessment of immune infiltration p value < 0.0001. We
could now strongly conclude that unsupervised hierarchical
clustering using genes of the PanCancer Immune Profiling array
allows to group breast cancer tumors according to gradual levels
of immune infiltration.
Immune clusters associate with prognosis. We examined the
immune clusters in perspective of survival using Kaplan–Meier
analysis and log-rank tests. For the two largest cohorts
METABRIC (n= 1904) and TCGA (n= 981), we found Cluster
B (with intermediate levels of immune infiltration) associated
with worse prognosis (Supplementary Fig. 3A, B). Such a worse
outcome for Cluster B cases was also observed when stratifying
for ER-negative (Supplementary Fig. 3C, D) and ER-positive cases
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Pathological assessment of immune infiltration Pathological assessment of immune infiltration
Fig. 1 Immune clusters are associated with total immune infiltration. a, d Gene expression was measured in 95 FFPE MicMa (a) and 1904 fresh frozen
METABRIC samples (d). Unsupervised clustering using correlation distance and ward. D linkage of the correlation matrix assesses the relation between
patients according to the expression of the genes on the PanCancer Immune Profiling array. All 760 genes on the array were used for clustering the MicMa
cohort, while 509 genes, which corresponds to genes (out of the 760) found in all datasets, were used to cluster the METABRIC. Annotations of the
samples on the top of the heatmap indicate histopathological features: PAM50 subtype, ER status as well as the three clusters identified by the cutree
method. b, e In the MicMa (b) and the METABRIC (e), lymphoid scores quantify lymphoid infiltration which was calculated from a set of genes’ markers of
lymphocyte as defined by the algorithm Nanodissect. Lymphoid scores are represented in boxplots according to immune clusters with Kruskal–Wallis test
p values. c, f H&E-stained tumor tissue samples (c, MicMa, n= 50 and f, METABRIC, n= 1904) were categorized by an experienced pathologist according
to the level of tumor-infiltrating immune cells. Boxplots represent the average lymphocyte score from Nanodissect according to pathologists’
classifications. Kruskal–Wallis test p values is denoted. The line within each box represents the median. Upper and lower edges of each box represent 75th
and 25th percentile, respectively. The whiskers represent the lowest datum still within [1.5 × (75th− 25th percentile)] of the lower quartile, and the highest
datum still within [1.5 × (75th− 25th percentile)] of the upper quartile.
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(Supplementary Fig. 3E, F) separately. To refine our observation,
we plotted patient survival according to Cluster B (light blue) vs
Clusters A and C (purple) and confirmed a clear and significant
worse prognosis for patients in Cluster B (Fig. 2). We further
validated this result in four additional cohorts with relevant
survival data: TAI (n= 327), VDX (n= 344), STK (n= 159), and
UPP (n= 251) (Supplementary Fig. 4). We concluded that
immune clusters associate with prognosis both in ER-negative
and ER-positive breast cancers.
Predicting immune clusters with binomial logistic regression.
Motivated by the clinical relevance of the immune clusters, we
aimed at developing a general method that could precisely and
sensitively predict the classification of patients to the worse
prognosis group without having to rely on unsupervised clus-
tering. We developed a model through training on 10 cohorts
(4546 samples) and testing on 5 others (1555 samples). We used
binomial logistic regression penalized by the lasso method to
obtain a set of genes (Supplementary Data 1) that sensitively and
specifically predict whether a sample is part of Cluster B or not, as
assessed by receiver operating characteristic curve and area under
the curve (AUC) analysis (Fig. 3a). Our model predicted the
immune clusters with an AUC= 85.8% (82.8%–88.7%). We
found that 96.3% of the samples assigned to Clusters A and C by
clustering were predicted to be A and C by the model, while
68.8% of the samples assigned to Cluster B through clustering
were found in Cluster B using the lasso method (Fig. 3b). It
appeared that the lasso method decreased the number of samples
in Cluster B (Fig. 3b). As unsupervised clustering is less reliable in
small cohorts and because learning the cluster assignment from
several cohorts will help to precise the phenotype underlying the
immune clusters, we hypothesized that the lasso-derived classi-
fication would be a better prognostic factor than the clustering
method. Indeed, by comparing the survival log-rank test p values,
we found that the lasso classification generally improved the
a
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Fig. 2 Immune clusters are associated with prognosis. Kaplan–Meier survival curves for Cluster B (light blue) and Clusters A and C (purple). In all
METABRIC (a) and TCGA (d) samples; in ER negative (b, e) and ER positive (c, f). p values are from log-rank tests. Kaplan–Meier display breast cancer-
specific survival for the METABRIC and relapse-free survival for the TCGA.
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significant associations between the immune clusters and survival
(Supplementary Table 3). The lasso model was validated in five
additional cohorts: Fig. 3c–e for STAM (n= 856), MAINZ (n=
200), and UPSA (n= 289) and Supplementary Fig. 5A, B for CAL
(n= 118) and PNC (n= 92).
As the binomial logistic regression only predicted two clusters
(Cluster B vs Clusters A and C), we performed another round of
binomial logistic regression to distinguish between Cluster A and
C with high accuracy (Supplementary Fig. 5C, D). In conclusion,
binomial logistic regression penalized by the lasso method refined
Cluster B and provided a single sample predictor that could be
applicable to every next patient in the clinic. In the subsequent
analyses, we use the categories given by the lasso methods as it
has a more significant association with survival.
Immune clusters, an independent prognostic factor. We further
investigated how the immune clusters were related to well-known
clinicopathological features in breast cancer (size, age, grade,
stage, lymph node involvement, and molecular subtypes
(PAM50)). Cluster A (with low immune infiltration) was enri-
ched in ER-positive and Luminal cases, while a higher proportion
of ER-negative and Basal-like cases was found in Cluster C (with
high immune infiltration) (Fig. 4a, b). ER-negative and ER-
positive samples as well as the PAM50 subtypes were equally
represented in the poor prognosis Cluster B (Fig. 4a, b).
We tested the prognostic impact of the immune clusters while
accounting for other prognostic factors using multivariable Cox
regression analysis. The variables available for each cohort (ER
status, PAM50 subtypes, age, nodal status, size, and grade) were
entered into each model. The odd ratios and p values associated
with each variable in each model are shown in Supplementary
Table 4. We found that immune clusters were an important factor
to model survival as shown by the significant p values
associated with immune clusters in each cohort Cox model.
Indeed, if we removed the immune clusters from the modeling,
the Akaike Information Criterion (AIC) index was increased
(Supplementary Table 5), demonstrating the important value of
immune clusters on top of all other variables for explaining breast
cancer survival.
To further test the strength of the immune clusters as an
important prognostic biomarker, we used a stepwise backward
selection. From the initial Cox models containing all variables,
we removed the weakest predictor variable only if this did not
weaken the model (as monitored by the calculation of AIC
index). This allowed us to find for each cohort the set of
variables explaining survival best. For all cohorts, the immune
clusters were kept in the best fitted minimal model, and in 9 out
of 11 cohorts, the immune clusters were a significant
prognostic variable (Table 1). To further emphasize and
illustrate the clinical relevance of the immune clusters and
their independence from the PAM50 molecular subtypes, we
plotted for the METABRIC and TCGA cohorts the



















Partial AUC: 85.8 (82.8–88.7)
c
























y p = 0.032
Clusters A & C (n = 720)
Cluster B (n = 130)
STAM cases
d
























l p = 0.013
Clusters A & C (n = 170)





Clusters A & C Cluster B
Model to predict clusters








Clusters A & C (n = 217)












Fig. 3 Prediction of Cluster B using binomial logistic regression. a Using binomial logistic regression penalized by the lasso method, we trained on
4546 samples to predict Cluster B. ROC curve assesses how the lasso output (the weighted gene sets in Supplementary Data 1) discriminates a sample to
be Cluster B or not. b For the 4546 samples in the training set, the heatmap represents whether a sample is part of Cluster B (light blue) or Clusters A and
C (purple), using the clustering or the lasso methods. c–e The prediction of the clusters (lasso) was tested on five cohorts, which were not included in the
training phase: c STAM (n= 856), d MAINZ (n= 200), and e UPSA (n= 289) are presented here, the two other cohorts CAL and PNC are presented in
Supplementary Figures. The association between predicted clusters and survival was tested using Kaplan–Meier survival curves for predicted Cluster B
(light blue) and predicted Clusters A and C (purple). p values are from log-rank tests. Kaplan–Meier display relapse-free survival for STAM, distant
metastasis-free survival for MAINZ, and overall survival for UPSA.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13329-5 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5499 | https://doi.org/10.1038/s41467-019-13329-5 | www.nature.com/naturecommunications 5
Validation in a new RNA-seq dataset with risk of recurrence
(ROR) scores. We generated a new dataset: EMIT0, which is a
subset of the OSLO2 cohort study. The OSLO2-EMIT0 was
assessed by the Food and Drug Administration-approved Pro-
signa risk of recurence (ROR) scores. As recently demonstrated,
ROR scores add significant prognostic information above stan-
dard clinicopathological features3,27. We assessed whether the
immune clusters could add prognostic value to ROR scores. We
found Cluster B composed of samples with intermediate ROR
scores compared to Clusters A and C (Fig. 4c). This suggested
that the poor prognosis associated with Cluster B was not likely to
be explained by the information contained in the ROR scores.
This observation was also true when assessing the ER-negative
(Supplementary Fig. 7A) and ER-positive (Supplementary
Fig. 7B) cases separately. For all cohorts, we calculated the ROR
scores following Parker et al.3’s method, which is related to
PAM50 subtyping3, and confirmed that Cluster B was composed
of intermediate ROR scores as exemplified in the METABRIC
cohort (Fig. 4d and Supplementary Fig. 7C, D).
Multivariable regression analysis confirmed that the immune
clusters bring additional prognostic value to the ROR scores
(Supplementary Table 6) as demonstrated by the significant
p values for the immune clusters when modeling survival with







































































































































Fig. 4 Immune clusters and clinicopathological features. a, b Average percentage of ER-positive and ER-negative samples (a) or PAM50 subtypes (b) of 15
cohorts across the clusters. Cluster A is enriched for ER-positive, Luminal A, Luminal B samples while a significantly higher percentage of ER-negative,
Basal-like, Her2-enriched samples was found in Cluster C (high infiltration). Asterisk (*) denote t test p value < 0.0001. Error bars represent standard error
to the mean. c Prosigna Breast Cancer ROR scores for the OSLO2-EMIT0 cohort were obtained from the NanoString nCounter Dx Analysis System using
FFPE breast tumor tissue. Boxplots represent the average Prosigna ROR scores in the immune clusters. Kruskal–Wallis test p value is denoted. d Calculated
ROR scores following the method of Parker et al.3 are compared to immune clusters using boxplots in the METABRIC cohort. Kruskal–Wallis test p values is
shown. e From eight breast cancer cohorts, in which the pathological complete response (pCR) was assessed after administration of neoadjuvant
chemotherapy, we calculated the percentage of responders in each cluster. Boxplots show the distribution of the percentage of responders in each
immune cluster. Kruskal–Wallis test p value is denoted. The line within each box represents the median. Upper and lower edges of each box represent 75th
and 25th percentiles, respectively. The whiskers represent the lowest datum still within [1.5 × (75th− 25th percentile)] of the lower quartile and the
highest datum still within [1.5 × (75th− 25th percentile)] of the upper quartile.
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reclassification improvement (NRI) and integrated discrimination
improvement (IDI) indexes28, we emphasized the additional
value of immune clusters to classify patients according to survival
when taken together with ROR scores, as indicated by the positive
NRI and IDI coefficients in all cohorts. Bootstrapping for
confidence interval (CI) construction for NRI and IDI showed
that, for several cohorts, the immune clusters significantly
improved patient classification according to prognosis when
added to the ROR scores (Supplementary Table 6). Using
complementary statistical analyses, we demonstrate the clinical
relevance of the immune clusters in breast cancer.
Immune clusters and response to neoadjuvant chemotherapy.
We further assessed the association between the immune clusters
and response to neoadjuvant chemotherapy, using gene expres-
sion data from studies in which patients were treated in neoad-
juvant setting (chemotherapy before surgery). The endpoint of
these studies was pathological complete response (pCR), which
means complete eradication of cancer cells at the end of the
chemotherapeutic regimen before surgery (see Supplementary
Table 2 for datasets used in this section). We used gene expres-
sion data from 8 studies (1377 samples), and assigned to each
sample its immune cluster belonging using the lasso method. As
shown in Fig. 4e, we found the highest percentage of responders
in Cluster C (59%), followed by Cluster A (30%) and the lowest
percentage of responders in Cluster B (11%). Since Cluster B is
also the smallest cluster in terms of patient numbers, we also
calculated the percentage of responders within each cluster.
Cluster C was composed in average of 42% of responders and
58% of patients with residual disease, whereas Cluster B had 18%/
82% and Cluster A 13%/87% of responders/residual disease cases,
respectively.
As the pCR rate differs as a function of ER status29, we also
calculated the percentage of responders in ER-positive and ER-
negative cases independently and found the lowest rate of
responders in Cluster B regardless of ER status (Supplementary
Fig. 8A, B, respectively).
For each cohort with response to neoadjuvant chemotherapy,
we assessed the distribution (chi-square p values, Supplementary
Table 7) of the pCR and non-pCR cases across the immune
clusters taking into account all cases, or ER-positive and ER-
negative cases independently. When considering the whole
cohort, we found the distribution of the responders significantly
different across immune clusters, with less responders in Cluster
B and most responders in Cluster C. When splitting by ER status,
the same tendency was observed although not always significant.
These results demonstrate that patients in Cluster C have a
higher probability to be responders, which corroborate previous
studies reporting a higher pCR rate for cases with high immune
infiltration and/or proliferative phenotype29,30. Our results also
highlight a low response rate in Cluster B, suggesting that
such patients may be candidates for testing of new neoadjuvant
therapeutic options.
In silico dissection of the immune clusters. To assess whether
the gradual immune infiltration in the clusters could explain the
association with prognosis, we tested which of the immune
clusters or total immune infiltration scores was more predictive of
survival in a Cox multivariable regression analysis (Supplemen-
tary Table 8). Nanodissect lymphocyte scores were poorly asso-
ciated with survival, we therefore hypothesized that specific
immune cell-type mixtures, rather than the total number of
immune cells in the tumor microenvironment, may explain the
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We estimated the proportions of 22 distinct immune cell types
using the CIBERSORT algorithm19. We calculated per cohort and
cluster the median infiltration of each immune cell type and
performed unsupervised clustering of such cell-type-specific
median infiltration scores (Fig. 5a). We found that the
CIBERSORT inferred immune infiltration recapitulated the
immune clusters. Cluster C cases were enriched, among other
cell types, for macrophages M1, memory activated T cells, and
follicular T helper cells (Fig. 5a), as also illustrated by the
distribution of the CIBERSORT scores in the METABRIC and the
TCGA cohorts (Fig. 5b and Supplementary Fig. 9). Cluster A had,
as expected, very low levels of immune cells. In the poor response
and prognosis Cluster B, higher levels of macrophages M2, resting
mast cells, and resting memory T cells were found (Fig. 5a), as
also illustrated by density plots for the METABRIC and TCGA
cohorts (Fig. 5b and Supplementary Fig. 9).
Using generalized linear models, we specified the immune cell
types distinguishing between Cluster B vs A–C and identified
resting and pro-tumorigenic immune cell types explaining Cluster B
(Fig. 5c). We also tested which immune cell types explained the
differences between Cluster A versus Cluster B (Supplementary
Fig. 10A) and between Cluster B versus Cluster C (Supplementary
Fig. 10B). When comparing Cluster A to Cluster B, all immune cell
types could explain Cluster B, indeed, Cluster A has no or low
immune infiltration. When comparing Cluster B to C, we found
again the pro-tumorigenic cell types macrophages M2 and resting
mast cells explaining Cluster B. These results suggest that pro-
tumorigenic immune infiltration in Cluster B may favor tumor
growth. In conclusion, Cluster A is composed of immune-cold
tumors, Cluster C contains immune-hot tumors, and cases
in Cluster B have a pro-tumorigenic immune infiltration.
Phenotypic analysis of the immune clusters. To further char-
acterize the phenotype associated with the poor prognosis in
Cluster B, we identified through differential gene expression
analysis the genes significantly overexpressed in Cluster B. We
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Fig. 5 In silico dissection of the immune clusters. a We used the CIBERSORT algorithm to assess the composition of the immune microenvironment of
breast cancer samples. For each cluster, we calculated the median of the absolute score of the 22 cell types given by the CIBERSORT in each cohort.
Immune cluster-specific cell-type median scores were used in an unsupervised clustering using maximum linkage and the ward.D2 method. The heatmap
obtained allows to visualize which cell types are enriched across the immune clusters. Immune clusters are annotated on the top and bottom of the
heatmap. b Density plots represents the distribution of the absolute CIBERSORT scores for selected cell types across the clusters for the METABRIC
cohort; the vertical lines crossing the distribution identify the median value for the score. Kruskal–Wallis test p value are denoted. c Estimates of
multivariable logistic regression analysis and the 95% confidence interval (CI) are illustrated by forest plot to assess which immune cells inferred by
CIBERSORT explain the most the poor prognosis cluster (Cluster B) vs Clusters A and C. Box size is inversely proportional to the width of the confidence
interval. Asterisks denote FDR-corrected p value < 0.05. Immune cell types from the lymphoid or myeloid lineage are identified.
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Cluster A and Cluster C separately (Bonferroni-corrected p value
< 0.0001; Supplementary Data 3). These genes were associated
with stem cell biology and EMT, as shown by the gene set
enrichment analysis (GSEA) using the H and C2 collection of the
MsigDB31 (Fig. 6a).
To further characterize the relationship between the immune
clusters and cancer cell phenotype, we used gene sets associated
with EMT, stem cells, hypoxia, and proliferation. In total, 11 gene
sets from the MsigDB and an additional EMT-related signature
from Tan et al.32 were selected (Supplementary Data 3). We
b
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Cluster B1 (n = 248)
Fig. 6 Immune clusters are associated with EMT and proliferation, two mutually exclusive phenotypes in breast cancer. a Genes overexpressed in Cluster B
were defined using Bonferroni-corrected differential expression analysis (Cluster B vs Cluster A and Cluster B vs Cluster C). Genes with significantly higher
expression in Cluster B were used in a gene set enrichment analysis using the C2 (white histograms) and H (gray histograms) collections of the MsigDB.
−Log10 p value of hypergeometric test are presented. The five most enriched processes in each collection are denoted. b Samples from each cohort (15
cohorts; 6101 samples) were scored using the GSVA Bioconductor package for enrichment in 12 pathways related to proliferation, EMT, and stem cells
(Supplementary Data 3). Average enrichment scores are calculated per immune cluster and cohort. Unsupervised clustering using maximum method and
ward. D2 linkage shows that pathways enrichment scores recapitulate the immune clusters. The numbers of samples in each cohort and immune clusters
are denoted. Immune cluster from which the median score originate are annotated. c Estimates of univariate logistic regression analysis and the 95%
confidence interval (CI) are illustrated by forest plot to assess which gene set signature scores calculated using GSVA associate with the poor prognosis
cluster (Cluster B) vs Clusters A and C. Box size is inversely proportional to the width of the confidence interval. Asterisks denote FDR-corrected p value <
0.05. d Correlation plots represent all the significant (FDR p value < 0.05) Spearman correlations between gene set signature scores and inferred immune
infiltration at the tumor site as calculated using the CIBERSORT algorithm. Color of the dots indicate positive (blue) or negative correlations (red). The size
of the dots is proportional to the Spearman Rho value. e Unsupervised clustering of 1318 Cluster B samples from 15 cohorts according to the gene set
signature scores using the correlation linkage and ward.D method allows to separate the samples in Cluster B with an EMT phenotype: Cluster B1 (green)
or proliferative phenotype: Cluster B2 (orange). PAM50 subtypes and ER status are annotated on the top of the heatmap. f, g Kaplan–Meier survival curves
for Cluster B1 (green) and Cluster B2 (orange). In all METABRIC (b) and TCGA (c) samples. p Values are from log-rank tests. Kaplan–Meier display breast
cancer-specific survival for the METABRIC and relapse-free survival for the TCGA.
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calculated per cluster and cohort an average gene set enrichment
score using the GSVA method; this score reflects the activity of each
pathway/gene set in an immune cluster33. Unsupervised clustering
of averaged-gene-set scores clearly separated the immune Clusters
A and C, while Cluster B was divided into two subgroups (Fig. 6b).
These results suggested an association between immune clusters
and the stem cell/EMT-related gene signatures.
Two mutually exclusive phenotypes in breast cancer. Through
unsupervised clustering of GSVA enrichment scores, we identi-
fied two mutually exclusive gene signatures in breast cancer, (i)
one associated with proliferation and embryonic stem cell-like
phenotype and (ii) and the other with EMT and mammary stem
cell phenotype.
A proliferative phenotype was dominating Cluster C (Supple-
mentary Fig. 11A), the same was observed when gene set scores
were calculated for each METABRIC sample (Supplementary
Fig. 11B). In Cluster B, the average gene set scores were either
high for EMT or proliferation-related signatures (Supplementary
Fig. 11C). At the sample level in the METABRIC, we observed a
similar pattern with samples having the one or the other state
activated (Supplementary Fig. 11D). Cluster A showed low scores
for both the EMT and proliferative states (Supplementary
Fig. 11E, F).
To formally identify which gene set scores explained Cluster B,
we tested how each gene set contribute to Cluster B vs Clusters A
and C using generalized linear models. EMT signatures
contributed positively to Cluster B while proliferation and cell
motility were associated with Clusters A and C (Fig. 6c). We also
tested which gene set score explained Cluster B when compared
separately to Cluster A (Supplementary Fig. 12A) or Cluster C
(Supplementary Fig. 12A). We found in both cases EMT scores
being a significant explanatory variable of Cluster B. However,
EMT signature scores alone were not of strong prognostic value
according to Cox regression analysis (Supplementary Table 9).
Overall, these results suggest a mutually exclusivity between EMT
and proliferation in breast cancers. They also suggest that only
when accompanied by a certain immune contexture the EMT or
the proliferative phenotype result in poor prognosis.
Correlation between tumor phenotype and immune infiltra-
tion. As immune clusters were associated with both (i) immune
cell types and (ii) gene set signatures, we formally assessed the
relation between immune infiltration (CIBERSORT) and cancer
cell characteristics (gene set scores). Figure 6d shows that the
proliferation and EMT scores correlate significantly with different
type of immune cells. Notably, high EMT scores are associated
with macrophages M2, resting mast cells, and resting memory
T cells while high proliferation is correlated with a more active
adaptive tumor microenvironment (macrophages M1, T helper
cells, activated dendritic cells, and active memory T cells). These
data suggest a continuum between the cancer cell phenotype and
the composition of the tumor microenvironment.
Heterogeneity in gene set scores within Cluster B. Cluster B was
dominated by samples with pro-tumorigenic immune infiltration
and high EMT signal; however, ~35% of Cluster B samples also
exhibited a proliferative phenotype. To explore this heterogeneity
within Cluster B, we grouped samples according to the gene
signature scores in an unsupervised manner into B1 dominated
by the EMT phenotype and B2 by the proliferation (Fig. 6e).
In the METABRIC and TCGA, B2 cases with the proliferative
phenotype had a worse outcome (Fig. 6f, g, also see Supplemen-
tary Fig. 13 in which survival probabilities of B1 and B2 are
plotted with Cluster A and Cluster C). While we were able to
identify a difference in survival between Cluster B1 and B2 in
METABRIC and TCGA, for other smaller cohorts, it was difficult
to conclude, as further splitting Cluster B resulted in small
groups. To further assess whether the heterogeneity in gene set
scores was accompanied by heterogeneity in immune contexture,
we sought for differences in specific immune cell types between
sub-clusters B1 and B2. Unsupervised clustering in Supplemen-
tary Fig. 14 showed that the two sub-clusters B1 and B2 both have
a pro-tumorigenic/resting immune microenvironment.
Altogether, the two mutually exclusive states within Cluster B
may be relevant in regard to prognosis; however; a unifying factor
of Cluster B is the presence of a pro-tumorigenic/resting immune
microenvironment.
Discussion
The tumor microenvironment plays an important role in breast
cancer pathogenesis. We provide a new immune-related subtype in
breast cancer with relevance for prognosis and response to
neoadjuvant chemotherapy in both ER-positive and ER-negative
cases. The herein described immune clusters are dependent on both
the abundance and composition of the immune infiltrate and are
independent of other prognostic factors, including PAM50.
Through unsupervised clustering using the expression of genes
part of the nCounter® PanCancer Immune Profiling Panel, we
identified in FFPE and fresh frozen breast tumors, three clusters
of patients. These clusters were (i) associated with total levels of
immune infiltration and with specific immune microenviron-
ment, (ii) provided an independent prognostic information, and
(iii) revealed two mutually exclusive breast cancer phenotypes.
As the immune clusters provided an independent prognostic
value in breast cancer, we developed a simple method that refined
and accurately predicted whether a sample falls in the poor
prognosis cluster (Cluster B) or not. We tested our method
successfully in 15 cohorts, spanning 6101 breast cancer samples.
We demonstrate using different and complementary statistical
approaches the strength of the immune cluster as a new prog-
nostic biomarker.
Through phenotypical characterization of the immune clusters,
we also identified two mutually exclusive states in breast cancers,
one associated with EMT and the other with proliferation. A
similar observation of two mutually exclusive states: proliferative
and EMT, was recently reported in a pan-cancer genomic analysis
of metastatic tumors34. Our study therefore suggests that such a
mutual exclusion could be extended to primary breast tumors and
possibly to other primary cancer types. The EMT process has
often been associated with metastasis35; it has been also pre-
viously suggested that transcription factors such as TWIST1,
which may drive the EMT process, need to be turned off for the
cancer cell to proliferate36. Such a mechanism may explain why
these two processes could not coexist in cancer cells.
Samples with the EMT or proliferative phenotype were found
in the poor prognosis cluster (Cluster B). About 65% of the
samples in Cluster B had an EMT-like phenotype. We further
found that this dominating phenotype could help explain Cluster
B when compared to Clusters A and C using generalized linear
models. As opposed to that, 35% of the samples in Cluster B had a
proliferative phenotype like most of the Cluster C samples. Pro-
liferation in Cluster C associated with infiltration of active anti-
tumorigenic immune cells, while proliferative samples in Cluster
B had infiltration of immune cells less likely to eradicate cancer
cells (macrophages M2, resting mast cells). This indicates that in
breast cancer a proliferative phenotype associated with a non-
adapted, pro-tumorigenic, resting immune microenvironment
relates to an adverse outcome as indicated by the Kaplan–Meier
analysis (Fig. 6f, g).
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Many studies have suggested that EMT drives an aggressive
tumor phenotype in breast cancer37,38. However, recent studies
have questioned the role of EMT in tumorigenesis, progression,
and metastasis39. Importantly, we show here that specific immune
infiltration is associated with the EMT process in breast cancer.
As a recent study also suggests40, we highlight that immune
contexture is an important factor to consider when evaluating the
role of EMT during cancer pathogenesis.
Using CIBERSORT19 to infer for specific immune cell infil-
tration, we found the EMT state highly correlated with infiltration
of resting mast cells, macrophages M2, natural killer (NK) cells,
and resting memory T cells. It has been previously suggested that
EMT could be associated with a pro-tumorigenic microenviron-
ment in lung cancer41. In esophageal squamous cell carcinoma,
M2 macrophages promote migration, invasion, and enhance
EMT42. On the other hand, mast cells have been associated with
angiogenesis in breast cancer43. Based on several gene expression
datasets, our current results demonstrate that the EMT process is
accompanied with infiltration of pro-tumorigenic/resting
immune cell types. The presence of antitumorigenic immune
cells, like NK cells, has also been found to be highly correlated
with the EMT in melanoma44.
In Cluster C, a proliferative phenotype was found to be cor-
related with infiltration of activated dendritic cells, T helper cells,
macrophages M1, and CD4 memory T cells. These cell types
reflect an antitumoral microenvironment. Cluster C is dominated
by both a highly proliferative phenotype and high infiltration of
antitumoral cell types. One may argue that chemotherapies may
successfully eradicate such proliferative tumors with the support
of an antitumoral microenvironment; explaining a better out-
come of these patients and the higher rate of responders to
neoadjuvant chemotherapy in Cluster C (Fig. 4e).
Low immune infiltration in Cluster A associated with neither
the proliferative nor the EMT state, which may indicate a less
aggressive tumor phenotype.
Previous studies have suggested that basal-like breast cancers
display a high metastatic ability associated with mesenchymal
features45. Sarrio et al.46 further showed that several markers of
EMT were upregulated in basal-like breast cancers46. Our study
shows using recent algorithms that the EMT phenotype is enri-
ched in Cluster B. In breast cancer, a recent gene transcriptional
profiling has identified an EMT gene expression signature asso-
ciated with claudin-low and metaplastic breast cancers47. How-
ever, the claudin-low subtype in the METABRIC cohort did not
correlate with Cluster B.
Our study suggests that targeting the primary pathways
involved in EMT such as transforming growth factor-b48, E-
Cadherin49, WNT/B-catenin pathway50, Notch51, hypoxia, or
tumor necrosis factor-alpha52 are interesting opportunities for
therapeutic intervention for patients with the worse prognosis
(Cluster B). More importantly, the macrophage re-education
strategy, which proposes to remodel M2 type of macrophages into
an anti-tumor, “M1-like” mode53, could be beneficial for Cluster
B patients.
In the era of modern immunotherapy, a few clinical trials using
immune checkpoint inhibitors have been conducted in breast
cancers and have been planned to be combined with immunogenic
chemotherapy or radiation therapy. The results of the first clinical
trials using monoclonal antibodies against immune checkpoint
inhibitors have recently been communicated and show some degree
of response especially in certain subpopulations54,55. Our study
suggests that considering both the immune cell types infiltrating the
tumor and the main state of the tumor (EMT or proliferative) will
precise treatment decisions and improve response to these new
treatment strategies.
Methods
Gene expression analysis from FFPE. Operable early breast cancer patients were
included in the Oslo1 micrometastasis observational study between 1995 and
199856. Informed consent has been obtained from all participants and the study
was approved by the local ethical committee (S-97103). FFPE were collected for a
subset of patient that also had fresh primary tumors collected for detailed mole-
cular analyses, a cohort called MicMa. Only patients within the MicMa (n= 96)
subset were included in the current analysis. FFPE tissue was first examined with
H&E staining to determine the tumor area and dissection was performed to mainly
include tumor tissue. RNA purification was performed using the Roche® High Pure
FFPET RNA Isolation Kit; ≥1–5 10-μm FFPE slides were used for each tumor. A
minimum of ∼100 ng of total RNA was used on the nCounter platform (Nano-
string Technologies, Seattle, WA, US) and the PanCancer Immune Profiling
Panel57. Data were normalized using all housekeeping genes and log base 2
transformed.
RNA-seq analysis of the OSLO2-EMIT0 cohort. The OSL2 breast cancer cohort
is a study collecting material from breast cancer patients with primary operable
disease in several hospitals in south-eastern Norway. Inclusion of patients started
in 2006 and is still ongoing. The study was approved by the Norwegian Regional
Committee for Medical Research Ethics (approval number 1.2006.1607, amend-
ment 1.2007.1125). Patients gave written consent for the use of material for
research purposes. All experimental methods performed are in compliance with the
Helsinki Declaration. Tumor tissue was cut into pieces and mixed before dis-
tribution to RNA extraction. RNA was isolated using the QIAgene kit Allprep
DNA/RNA/miRNA universal on the QIAcube machine and method (Qiagen).
Quality control was performed by Nanodrop ND-1000 (NanoDrop Technologies)
and BioAnalyzer 2100 (Agilent) analysis. All RNA had RNA Integrity Number
(RIN) ≥ 6. We used Illuminas TruSeq Stranded mRNA Library Prep Kit for the
automated NeoPrep Library Prep System (Illumina). Starting amount was 120 ng
total RNA and we used Illuminas NextSeq500 sequencers (2 × 75 bp). Raw
sequencing read data were demultiplexed and filtered using Bowtie2 against
ribosomal, phiX174, and UCSC RepeatMasker sequences. The sequence data were
processed as described previously.58 Log-transformed FPKM RNA-seq gene
expression data at GEO are available at GSE135298. Raw data are available at
EGAS00001003631.
Data collection and processing. Publicly available expression data from breast
cancer cohorts were used in this study. Patients’ consents and ethical approval are
available in the respective original articles the datasets were published with (Sup-
plementary Table 2). Expression data were obtained from Gene Expression
Omnibus, the European Genome-phenome Archive, ArrayExpress, or TCGA data
portals. For survival analyses, we selected studies with >100 samples and relevant
survival data from patients with invasive breast tumors sampled at the time of
surgical resection without neoadjuvant treatment. Survival data were of four types:
relapse-free survival, distant metastasis-free survival, OS, or breast cancer-specific
survival.
For analysis of response to neoadjuvant chemotherapy, we selected cohorts of
patients treated with a chemotherapeutic regimen and for which gene expression
has been profiled from the primary tumor prior to treatment. pCR was assessed at
the time of surgery at the end of treatment and refers to the total elimination of
cancer cells at surgery.
Except for the METABRIC cohort for which the ER status has been extensively
used and defined, we used gene expression data together with the R package optim
to systematically infer for ER status using a two-component Gaussian finite
mixture model using maximum likelihood estimation as previously described59.
Classification into the PAM50 intrinsic molecular subtypes was performed based
on gene expression data using the genefu package in R3.
Gene set enrichment analysis. Gene set enrichment analysis was performed using
the Molecular Signatures Database v4.0 (MSigDB31) H and C2 collections.
Enrichment was assessed by hypergeometric testing.
Unsupervised clustering to obtain immune clusters. First a correlation matrix
was calculated to assess the dependence between samples initially based on the
expression of the 760 genes in the nCounter® PanCancer Immune Profiling Panel
and later with the 509 genes that are present in all clustered datasets (training in
Supplementary Table 2). Hierarchical clustering of patients’ correlation matrix was
performed using the R package pheatmap v1.0.12 using correlation as clustering
distance and ward.D as linkage. Clusters were identified using the cutree function.
To determine the optimal number of clusters for each cohort, we used the sil-
houette analysis of KMeans using the cluster R package; for most of the cohorts
assessed, three clusters was a better pick than more numerous clusters.
Nanodissect analysis, lymphoid and myeloid scores. The algorithm Nanodissect
(http://nano.princeton.edu) was used as previously described to predict for lym-
phoid and myeloid infiltration24,25. Breast collection data (May 2013), which
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contains 17,940 genes measured on 622 arrays, was inspected for genes specifically
expressed in lymphoid or myeloid cell types and not expressed in mammary gland
or mammary epithelium. The genes with >65% probability to be positive lym-
phocyte- or myelocyte-specific standard genes as opposed to mammary gland or
epithelium were used in downstream analysis. Nanodissect scores for lymphocyte
or myelocyte infiltration reflect the average expression of the respective genes
(Supplementary Data 4) in a sample.
CIBERSORT analysis. The algorithm CIBERSORT was used on normalized
expression data to infer the absolute proportions of 22 types of infiltrating
immune cells. CIBERSORT is a deconvolution algorithm that uses a set of
reference gene expression values (547 genes) to predict 22 immune cell type
proportions from bulk tumor sample expression data by using support vector
regression19. To assess the reliability of the deconvolution method, CIBERSORT
derives a p value for each sample. CIBERSORT software package was obtained
from the developers, and analysis was performed by using the default signature
matrix at 1000 permutations.
Single-sample GSEA (GSVA). Gene set analysis was carried out using the GSVA
Bioconductor package v1.30.033. We curated gene sets for various epithelial
mesenchymal transition, stem cell, proliferation, and cell cycle-related pathways
(Supplementary Data 3). For each sample, a score for the enrichment of a set of
genes using gene expression profile was obtained.
Binomial logistic regression to predict immune clusters. We used binomial
logistic regression through the glmnet v2.0–16R package60 to develop a method
that allows to assign any given sample to the group with the worse prognosis or not
without resorting to unsupervised clustering. This predictor method is highly
efficient for smaller cohorts and allow to assign class to single samples. To perform
the analysis, we mean centered datasets and set up a logistic regression using the
binomial distribution to predict categorical response of the two possible outcomes:
being in the bad prognosis group or not. This approach gave a signature of target
genes that together captured the variation associated with the two categories
(Supplementary Data 1).
Patients were divided into Cluster B or Clusters A and C groups according to





where g is the target (gene), n is the number of targets, βg is the lasso coefficient for
target gene and Xgi is the gene expression value in sample i. If index for patient i is
higher than the intercept= 1.206538657, sample is assigned to Cluster B.
Pathological assessment of immune infiltration. Vascular invasion, inflamma-
tory cell infiltrate, and necrosis, including relation of tumor cells/tumor stroma,
were evaluated on slides stained with H&E as previously described61. Using a
simple microscope, subjective categorization of inflammatory cell infiltrate into the
categories of “low,” “moderate,” “high,” and “severe” was performed based on the
frequency of mononuclear inflammatory cell infiltration observed in the
invasive tumor.
ROR score calculation. ROR scores for each sample were calculated as described
in ref. 3, ROR-Score= 0.05 × Basal+ 0.12 × Her2-enriched− 0.34 × Luminal A+
0.23 × Luminal B; where Basal, Her2-enriched, Luminal A, and Luminal B are the
correlation of each sample to the centroid obtained using the genefu package in R.
Statistical, survival, multivariable Cox regression analysis. All analyses were
performed in the R version 3.3.2. Unless otherwise stated, results were considered
statistically significant, if p value < 0.05. Kaplan–Meier estimator and log-rank tests
were performed using the functions Surv, survfit, and survdiff (R package survival
v2.42–3). Multivariable Cox regression analyses were used to test the independent
prognostic value of the immune clusters using the R package survival and the
coxph function. Mann–Whitney U or Kruskal–Wallis tests were used to assess
statistical significance within boxplots.
In the box-and-whisker plots, the line within each box represents the median.
Upper and lower edges of each box represent 75th and 25th percentile, respectively.
The whiskers represent the lowest datum still within [1.5 × (75th− 25th
percentile)] of the lower quartile and the highest datum still within [1.5 × (75th−
25th percentile)] of the upper quartile.
To identify differentially expressed genes between clusters, we used a t test
followed by Bonferroni correction of the p value. A strict corrected p value (p <
0.0001) was used to identify differentially expressed genes.
NRI and IDI were calculated using the survIDINRI v1.1–1 R package. To assess
the 95% CI and p values for the IDI and NRI, a standard bootstrap method was
used with resampling performed 500 times. NRI and IDI were assessed at the
maximum follow-up time as presented in the Kaplan–Meier survival analysis to
assess the improvement in performance of the survival model.
Forest plots were obtained using the forestplot v1.7.2 R package and represent
for the univariate and multivariate analysis the hazard ratio and their 95% CI.
Boxes represent hazard ratios and are inversely proportional to the width of the CI,
horizontal lines are 95% CI.
Correlation plot using the corrplot v0.84 package visualizes Spearman
correlations, only False Discovery Rate-corrected significant correlation are
visualized and colored according to directionality of the rho values. Size of the dots
are proportional to the rho value.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data used in this study are publicly available or can be downloaded through the
European Genome-phenome Archive (EGA)—EMBL-EBI portal. We mainly used gene
expression datasets from breast cancers in this study summarized in Supplementary
Table 2. Data were downloaded with the study-specific normalization process. For initial
clustering of the correlation matrix, no other normalization was performed. Further on,
for binomial logistic regression and further downstream analysis (CIBERSORT, GSVA,
differential expression) the datasets were mean centered. The source data underlying all
Figures and Supplementary Figures are available in a source data file. The newly
generated RNA-seq gene expression data for the breast cancer cohort OSLO2-EMIT0 is
available at EGA with accession number EGAS00001003631. Log-transformed FPKM
RNA-seq gene expression data at GEO are available at GSE135298. Newly generated,
normalized log 2-transformed nCounter counts for the MicMa cohorts can be found in
Supplementary Data 5.
Code availability
To reproduce all figures published in this study, we provide all codes and relevant data in
a source data file. In addition, the code to subtype the immune clusters are available
online at http://eurostar.nebdal.no:5000/ as well as the codes to subtype using R or
python are available at https://github.com/dnebdal/clusterscore.
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